| [1] |
JIAO Yuzhu, LI Huijie, YANG Qing.
Update on off-label use of upadacitinib in dermatology
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(9): 692-696.
|
| [2] |
BAI Fan, YU Wanlong, XU Yabo, FAN Lifang, LIU Yuyuan, TIAN Zan, LEI Mingjun.
Efficacy of abrocitinib in the treatment of moderate-to-severe prurigo phenotype atopic dermatitis
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(8): 593-597.
|
| [3] |
CAO Shan, ZHAO Qing, HUAI Pengcheng, ZHANG Furen.
Tofacitinib monotherapy successfully treated pemphigus vulgaris: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(7): 522-523.
|
| [4] |
LIU Mingyue, TAN Shuhui, ZHANG Zhe, NIE Zhenhua.
Update of the treatment for bullous pemphigoid
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(7): 538-542.
|
| [5] |
YUAN Mingzhu, LI Ruyi, SUN Yi, ZHANG Wen.
Severe alopecia areata unresponsive to baricitinib susessfully treated with upadacitinib: two cases report
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(4): 283-287.
|
| [6] |
SUN Jianlin, ZHANG Yingqi, HAN Jianwen, WU Riga.
Vasculitis successfully treated with JAK inhibitor: three cases report
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(4): 290-294.
|
| [7] |
ZHAO Anqi, LIU Hong.
Off-label prescriptions of JAK inhibitor in dermatology
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(4): 303-307.
|
| [8] |
FU Fanghui, MA Lei, LI Yuan, HU Haiyou, ZHANG Xi, GAO Yu, FU Wenjing.
Acquired reactive perforating collagenosis successfully treated with tofacitinib: a case report and literature review
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(3): 198-201.
|
| [9] |
CHEN Yan, ZHANG Peilian.
Progress in the treatment of pemphigus vulgaris
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(3): 234-238.
|
| [10] |
YUAN Ruiqing, ZHOU Guizhi, LIU Hong.
Tofacitinib in the treatment of primary cutaneous amyloidosis: a case report and literature review
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(1): 51-54.
|
| [11] |
WU Kaiyue, LIU Xinzhou, CHEN Xuechao, ZHOU Guizhi, LIU Guoyan.
Upadacitinib for the treatment of twenty-nail dystrophy: a case report
[J]. China Journal of Leprosy and Skin Diseases, 2025, 41(1): 66-68.
|
| [12] |
YU Fangzhou, YANG Baoqi.
Update of tofacitinib in dermatology
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(9): 678-682.
|
| [13] |
YAN Yuanyuan, ZHAO Yanxia, CHENG Yu.
Update of Janus kinase inhibitors in the treatment of vitiligo
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(7): 519-523.
|
| [14] |
GE Susu, WANG Fanghai, SUN Yuhan, YUAN Zhong.
A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for upadacitinib
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(7): 466-470.
|
| [15] |
CUI Yinling, XU Fanli, CAO Shan, XUE Xiaotong, ZHAO Qing, LIU Yongxia, LIU Hong, ZHANG Furen.
Abrocitinib in the treatment of cutaneous lichen planus: two cases and literature review
[J]. China Journal of Leprosy and Skin Diseases, 2024, 40(6): 412-415.
|